Comparison of Early and Late Administration of Convalescent Plasma for the Treatment of COVID-19 Patients Hospitalized in Intensive Care Unit Retrospectively
Duygu Kayar Çalılı, Abdullah Ömer Atsal, Belgin Tunçtürk Akan, H. Ankarali, Canan Çam Gönen, Işıl Özkoçak Turan
{"title":"Comparison of Early and Late Administration of Convalescent Plasma for the Treatment of COVID-19 Patients Hospitalized in Intensive Care Unit Retrospectively","authors":"Duygu Kayar Çalılı, Abdullah Ömer Atsal, Belgin Tunçtürk Akan, H. Ankarali, Canan Çam Gönen, Işıl Özkoçak Turan","doi":"10.54875/jarss.2023.38233","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to compare laboratory and outcome of the patients who were hospitalized in the intensive care unit with the diagnosis of Coronavirus Disease-19 (COVID-19) and transfused convalescent plasma based on timing of treatment. Methods: Patients administered 200 mL of convalescent plasma were analysed retrospectively. Based on symptoms’ onset, patients were divided into two groups as early (≤ 7 days) and late (> 7 days) plasma treatment groups. Patients’ characteristics, comorbidities, treatments, laboratory (pre-transfusion, day 1 and day 3 after transfusion) and outcome were evaluated according to groups. Results: A total of 152 patients matched criteria. There was no difference between the early (n=82) and late (n=70) treatment groups in terms of demographic characteristics, comorbidities, treatments, outcomes. Ferritin levels were higher in the early treatment group than in the late treatment group on before transfusion and day 1 (p=0.023, p=0.015). C reactive protein value was lower in the late treatment group on day 3 (p=0.011). Comparing the rate of change between day 1 and day 3 of treatment, it was observed that the changes in ferritin and fibrinogen values were higher in the late group than in the early group (p=0.014, p=0.049). There was no difference between the groups in other laboratory values and outcome. Conclusion: In our study, we observed that the timing of convalescent plasma had no significant effect on outcome. However, more evidence was needed to prove the difference in laboratory results. Keywords: Intensive care unit, COVID-19, convalescent plasma, mortality","PeriodicalId":36000,"journal":{"name":"Anestezi Dergisi","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anestezi Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54875/jarss.2023.38233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: We aimed to compare laboratory and outcome of the patients who were hospitalized in the intensive care unit with the diagnosis of Coronavirus Disease-19 (COVID-19) and transfused convalescent plasma based on timing of treatment. Methods: Patients administered 200 mL of convalescent plasma were analysed retrospectively. Based on symptoms’ onset, patients were divided into two groups as early (≤ 7 days) and late (> 7 days) plasma treatment groups. Patients’ characteristics, comorbidities, treatments, laboratory (pre-transfusion, day 1 and day 3 after transfusion) and outcome were evaluated according to groups. Results: A total of 152 patients matched criteria. There was no difference between the early (n=82) and late (n=70) treatment groups in terms of demographic characteristics, comorbidities, treatments, outcomes. Ferritin levels were higher in the early treatment group than in the late treatment group on before transfusion and day 1 (p=0.023, p=0.015). C reactive protein value was lower in the late treatment group on day 3 (p=0.011). Comparing the rate of change between day 1 and day 3 of treatment, it was observed that the changes in ferritin and fibrinogen values were higher in the late group than in the early group (p=0.014, p=0.049). There was no difference between the groups in other laboratory values and outcome. Conclusion: In our study, we observed that the timing of convalescent plasma had no significant effect on outcome. However, more evidence was needed to prove the difference in laboratory results. Keywords: Intensive care unit, COVID-19, convalescent plasma, mortality